Zhejiang Better Pharmaceuticals Co. Ltd.

Primary Objective: In accordance with relevant bioequivalence testing regulations, mesalazine enteric-coated tablets (trade name: Salofalk, strength: 0.5g), manufactured by Dr. Falk Pharma GmbH, was selected as the reference formulation. A human bioequivalence study was conducted on the test formulation mesalazine enteric-coated tablets (strength: 0.5g) manufactured and supplied by Zhejiang Beide Pharmaceutical Co., Ltd., under fasting and postprandial administration conditions. The study compared the absorption rate and extent of absorption of the drug in the test formulation with the reference formulation to determine if the differences were within acceptable limits, and evaluated the bioequivalence of the two formulations under fasting and postprandial administration conditions. Secondary Objective: To observe the safety of oral administration of the test formulation mesalazine enteric-coated tablets (strength: 0.5g) and the reference formulation mesalazine enteric-coated tablets (trade name: Salofalk, strength: 0.5g) to healthy participants.

The main purpose of the study is to study the pharmacokinetics of the test preparation finerenone tablets (specification: 20 mg, produced by Zhejiang Beide Pharmaceutical Co., Ltd.) and the reference preparation finerenone tablets (trade name: Kerendia®; specification: 20 mg; produced by Bayer AG) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study is to evaluate the safety of the test preparation finerenone tablets (specification: 20 mg) and the reference preparation finerenone tablets (trade name: Kerendia®, specification: 20 mg) in healthy subjects.

To investigate the pharmacokinetic characteristics of a single oral dose of lacidipine tablets (test preparation T, strength: 6 mg) provided by Zhejiang Beide Pharmaceutical Co., Ltd. and a single oral dose of lacidipine tablets (reference preparation R, trade name: Lacipil®, strength: 6 mg) certified by GlaxoSmithKline S.p.A. in healthy subjects under postprandial conditions, evaluate the bioequivalence and safety of the two preparations, and provide a basis for the registration application of the test preparation.